slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 42,121-42,150
Pages 2,019
Rows per page 30
Component
42,121-42,150 of 60,557
08
The table lists specific line items like D&A, share-based payments, and tax expenses to bridge net income to Adjusted EBITDA.Nexters | Results Presentation Deck | 8 slides · GDEV Inc.
Conference presentation Investor relations 1 hit
08
The slide details a capital raise structure involving senior secured notes and warrants.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
06
The slide uses a map of California to visualize station locations and a table to provide granular project details.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
10
Includes footnotes regarding restricted cash, FFI acquisition, share registration, and adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
11
Includes footnotes detailing stock-based compensation components.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
16
Includes a footnote regarding adjustments for Q4 2022 and Q1 2023.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
17
The table includes a footnote regarding adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
18
The table includes a footnote regarding Q4 2022 and Q1 2023 adjustments related to Romeo Power.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
15
Includes a detailed table of Phase 2 cohorts and a list of study objectives.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Clinical trial data presentation for NVL-520.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
28
The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a timeline-style layout to represent drug development stages.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
The slide uses a numbered list format to categorize the problem into four distinct areas: clinical outcomes, cost/length of stay, reimbursement losses, and readmission penalties.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
12
Includes logos for UChicago Medicine and Lenox Hill Hospital/Northwell Health.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
18
The slide highlights high survival rates, particularly in the <10kg group which traditionally receives no therapy.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
22
The slide uses a color-coded legend to distinguish between clinical, commercial, product, and partnership milestones.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
05
Includes non-GAAP financial measures footnote.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Is1 hit
11
Includes a performance summary table showing CAGR for Share Price and TBVPS.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
15
Includes footnotes regarding CECL adoption, subordinated debentures, and non-GAAP reconciliation.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · New Bliss1 hit